| Name | Title | Contact Details |
|---|---|---|
Ashley Mahoney |
Senior Manager, Sales Operations | Profile |
Amanda Mikus |
Senior Director, Sales Operations and BI | Profile |
Ira Duarte |
Chief Financial Officer | Profile |
Lynda Harris |
Senior Director of Human Resources | Profile |
Nancy Knochel Clodfelter |
Human Resources Director | Profile |
Highland Park Healthcare Inc is a Highland Park, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Praestan Health is a new health technology company that is building a precision-guided suite of health and wellbeing applications to support practitioners and individuals in efficient, effective, and sustainable health behavior change.
CancerLinQ, a subsidiary of ASCO, is a mission-driven, non-profit health technology company focused on improving quality of care, advancing biomedical research, and improving health outcomes for all patients with cancer. Backed by ASCO, CancerLinQ`s products and services reflect a deep understanding of the needs of oncologists, cancer centers, and researchers. We are bilingual by design: fluent in both the language of oncology and technology. As a trusted partner to over 100 cancer centers and community oncology practices, CancerLinQ is uniquely positioned to advance cancer care and research.
Senior Whole Health is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Senior Whole Health is based in Cambridge, MA. You can find more information on Senior Whole Health at www.seniorwholehealth.com
Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.